United States securities and exchange commission logo




                                                                                
                               June 10, 2024

       Weilai (Will) Zhang
       Chief Executive Officer
       Antelope Enterprise Holdings Limited
       Room 1802, Block D, Zhonghai International Center
       Hi-Tech Zone, Chengdu
       Sichuan Province, PRC

                                                        Re: Antelope Enterprise 
Holdings Limited
                                                            Registration 
Statement on Form F-1
                                                            Filed May 24, 2024
                                                            File No. 333-279733

       Dear Weilai (Will) Zhang:

              We have conducted a limited review of your registration statement 
and have the
       following comments.

              Please respond to this letter by amending your registration 
statement and providing the
       requested information. If you do not believe a comment applies to your 
facts and circumstances
       or do not believe an amendment is appropriate, please tell us why in 
your response.

              After reviewing any amendment to your registration statement and 
the information you
       provide in response to this letter, we may have additional comments.

       Registration Statement on Form F-1

       Cover Page

   1.                                                   Please disclose 
prominently on the prospectus cover page that you are not a Chinese
                                                        operating company but a 
British Virgin Islands holding company with operations
                                                        conducted by your 
subsidiaries based in China and that this structure involves unique risks
                                                        to investors. Your 
disclosure should acknowledge that Chinese regulatory authorities
                                                        could disallow this 
structure, which would likely result in a material change in your
                                                        operations and/or a 
material change in the value of the securities you are registering for
                                                        sale, including that it 
could cause the value of such securities to significantly decline or
                                                        become worthless. 
Provide a cross-reference to your detailed discussion of risks facing the
                                                        company and the 
offering as a result of this structure. Additionally, please confirm, if true,
                                                        that you do not use a 
variable interest entity structure.
 Weilai (Will) Zhang
Antelope Enterprise Holdings Limited
June 10, 2024
Page 2
Prospectus Summary, page 1

2.       In your summary of risk factors, disclose the risks that your 
corporate structure and being
         based in or having the majority of the company   s operations in China 
poses to investors.
         In particular, describe the significant regulatory, liquidity, and 
enforcement risks with
         cross-references to the more detailed discussion of these risks in the 
prospectus. For
         example, specifically discuss risks arising from the legal system in 
China, including risks
         and uncertainties regarding the enforcement of laws and that rules and 
regulations in
         China can change quickly with little advance notice; and the risk that 
the Chinese
         government may intervene or influence your operations at any time, or 
may exert more
         control over offerings conducted overseas and/or foreign investment in 
China-based
         issuers, which could result in a material change in your operations 
and/or the value of the
         securities you are registering for sale. Acknowledge any risks that 
any actions by the
         Chinese government to exert more oversight and control over offerings 
that are conducted
         overseas and/or foreign investment in China-based issuers could 
significantly limit or
         completely hinder your ability to offer or continue to offer 
securities to investors and
         cause the value of such securities to significantly decline or be 
worthless.
Risk Factors, page 12

3.       Given the Chinese government   s significant oversight and discretion 
over the conduct of
         your business, please revise to highlight separately the risk that the 
Chinese government
         may intervene or influence your operations at any time, which could 
result in a material
         change in your operations and/or the value of the securities you are 
registering. Also,
         given recent statements by the Chinese government indicating an intent 
to exert more
         oversight and control over offerings that are conducted overseas 
and/or foreign investment
         in China-based issuers, acknowledge the risk that any such action 
could significantly limit
         or completely hinder your ability to offer or continue to offer 
securities to investors and
         cause the value of such securities to significantly decline or be 
worthless.
Enforceability of Civil Liabilities, page 111

4.     You disclose here that many of your officers and directors, and some of 
the experts named
       in this prospectus, are residents of PRC or elsewhere outside of the 
U.S., and all of our
       assets and the assets of such persons are located outside the U.S. and 
as a result, it may be
       difficult for investors in the U.S. to effect service of process within 
the U.S. upon such
       directors, officers and representatives of experts who are not residents 
of the U.S. or to
       enforce against them judgments of a U.S. court predicated solely upon 
civil liability under
       U.S. federal securities laws or the securities laws of any state within 
the U.S. Please revise
FirstName LastNameWeilai (Will) Zhang
       to clarify if you have any officers or directors in the U.S. 
Additionally, please revise to
Comapany    NameAntelope
       include  a risk factor Enterprise
                              addressingHoldings   Limited
                                         the difficulty of bringing actions 
against these individuals
       and
June 10,    enforcing
         2024   Page 2 judgments against them.
FirstName LastName
 Weilai (Will) Zhang
FirstName  LastNameWeilai
                    Holdings(Will) Zhang
Antelope Enterprise          Limited
Comapany
June       NameAntelope Enterprise Holdings Limited
     10, 2024
June 10,
Page 3 2024 Page 3
FirstName LastName
General

5.       We note you disclosed certain material terms of the equity line 
agreement. Please also
         disclose the following material terms of each equity line agreement, 
including: (1) the
         maximum principal amount available under the agreement; and (2) the 
term of the
         agreement.
6.       Please revise to disclose the natural person or persons who exercise 
the voting and/or
         dispositive powers, or have the right to receive the economic benefit, 
with respect to the
         three equity line investors.
7.       We note that you entered into equity line agreements with three 
different entities. Please
         clarify whether there is any relationship between the three equity 
line investors.
         Additionally, please confirm, if true, that these investors are not 
related parties of the
         company.
8.       Please file the executed equity line agreements with the three equity 
line investors as
         exhibits.
        We remind you that the company and its management are responsible for 
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action 
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please 
allow adequate
time for us to review any amendment prior to the requested effective date of 
the registration
statement.

       Please contact Uwem Bassey at 202-551-3433 or Mitchell Austin at 
202-551-3574 with
any other questions.



                                                               Sincerely,

                                                               Division of 
Corporation Finance
                                                               Office of 
Technology
cc:      Joan Wu